IL217149A0 - Compositions and methods for treating parkinson's disease - Google Patents

Compositions and methods for treating parkinson's disease

Info

Publication number
IL217149A0
IL217149A0 IL217149A IL21714911A IL217149A0 IL 217149 A0 IL217149 A0 IL 217149A0 IL 217149 A IL217149 A IL 217149A IL 21714911 A IL21714911 A IL 21714911A IL 217149 A0 IL217149 A0 IL 217149A0
Authority
IL
Israel
Prior art keywords
disease
compositions
methods
treating parkinson
parkinson
Prior art date
Application number
IL217149A
Other languages
English (en)
Original Assignee
Clera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clera Inc filed Critical Clera Inc
Publication of IL217149A0 publication Critical patent/IL217149A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL217149A 2009-07-31 2011-12-22 Compositions and methods for treating parkinson's disease IL217149A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23026409P 2009-07-31 2009-07-31
PCT/CA2010/001185 WO2011011886A1 (en) 2009-07-31 2010-07-30 Compositions and methods for treating parkinson's disease

Publications (1)

Publication Number Publication Date
IL217149A0 true IL217149A0 (en) 2012-02-29

Family

ID=43528672

Family Applications (1)

Application Number Title Priority Date Filing Date
IL217149A IL217149A0 (en) 2009-07-31 2011-12-22 Compositions and methods for treating parkinson's disease

Country Status (12)

Country Link
US (1) US9192605B2 (enExample)
EP (1) EP2459194A4 (enExample)
JP (1) JP5756105B2 (enExample)
KR (1) KR20120103557A (enExample)
CN (1) CN102548555A (enExample)
AU (1) AU2010278645A1 (enExample)
BR (1) BR112012008193A2 (enExample)
CA (1) CA2769149A1 (enExample)
IL (1) IL217149A0 (enExample)
MX (1) MX2012001290A (enExample)
NZ (1) NZ598247A (enExample)
WO (1) WO2011011886A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3178035A1 (en) 2012-12-24 2014-07-03 Neurogastrx, Inc. Methods for treating gi tract disorders
JP6371716B2 (ja) * 2014-04-01 2018-08-08 東京エレクトロン株式会社 基板液処理装置及び基板液処理方法並びに基板液処理プログラムを記録したコンピュータ読み取り可能な記録媒体
WO2015200369A1 (en) 2014-06-24 2015-12-30 Neurogastrx, Inc. Prodrugs of metopimazine
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
CN114601928B (zh) * 2022-04-02 2023-03-17 首都医科大学 一种钙超载介导神经元死亡的标志物及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1219667B (it) * 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
RU2057529C1 (ru) * 1994-05-30 1996-04-10 Алексей Михайлович Коршунов Способ лечения синдрома паркинсонизма
US20010056101A1 (en) * 1998-06-29 2001-12-27 Carol A. Tamminga Use of dopamine receptor antagonists in combination with partial dopamine agonist to prevent tolerance in treating nervous disorders related to dopamine dysfunction
DE10111486A1 (de) * 2001-03-09 2002-10-02 Ralph R Dawirs Verwendung einer oder mehrerer neuroaktiver Substanzen zur Behandlung der Parkinsonschen Krankheit
ES2286453T3 (es) * 2002-09-17 2007-12-01 Motac Neuroscience Limited Tratamiento de la discinesia.
CN1802153A (zh) * 2002-10-22 2006-07-12 药物滥用科学研究公司 用选择性多巴胺d1受体激动剂治疗认知损害
CA2628298A1 (en) * 2004-11-03 2006-05-11 Clera Inc. Method to detect dopamine receptors in the functional d2high state
AU2009212065B2 (en) * 2008-02-05 2014-03-20 Clera Inc. Compositions and methods for alleviating depression or improving cognition

Also Published As

Publication number Publication date
CA2769149A1 (en) 2011-02-03
US9192605B2 (en) 2015-11-24
EP2459194A4 (en) 2012-12-19
JP2013500943A (ja) 2013-01-10
AU2010278645A1 (en) 2012-03-08
CN102548555A (zh) 2012-07-04
US20120115910A1 (en) 2012-05-10
JP5756105B2 (ja) 2015-07-29
BR112012008193A2 (pt) 2016-03-01
NZ598247A (en) 2014-01-31
MX2012001290A (es) 2012-06-12
WO2011011886A1 (en) 2011-02-03
EP2459194A1 (en) 2012-06-06
KR20120103557A (ko) 2012-09-19

Similar Documents

Publication Publication Date Title
IL205153A0 (en) Compositions for treating parkinson's disease
IL202015A0 (en) Methods and compositions for treating skin conditions
IL209032A0 (en) Compositions and methods for treating digestive disorders
ZA200908711B (en) Methods and compositions for treating allergic diseases
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
PL2985032T3 (pl) Glyx do stosowania do leczenia choroby alzheimera, choroby parkinsona lub choroby huntingtona
PL3208612T3 (pl) Kompozycje i sposoby leczenia chorób o podłożu immunologicznym
ZA201001810B (en) Seed treatment compositions and methods
ZA201001811B (en) Seed treatment compositions and methods
EP2707369A4 (en) COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
PT2200431T (pt) Novos métodos e composições para o tratamento do cancro
IL217774A0 (en) Compositions for treating gaucher disease and uses thereof
EP2429584A4 (en) TREATMENT PROCEDURE AND COMPOSITIONS
PL2340042T3 (pl) Sposoby i kompozycje do leczenia raka
EP2244690A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES AND DRESSES
PL2349231T3 (pl) Kompozycje i metody leczenia chorób kopyta
EP2485733A4 (en) METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
SG11201403272YA (en) Compositions and methods for treating alzheimer's disease
IL210097A0 (en) Compositions and methods for treating unfluenza
IL209336A0 (en) Compositions for treating hyperproliferative diseases and uses thereof
EP2271352A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEOPLASTIC DISEASE
IL210840A0 (en) Methods and compositions for treating and preventing autoimmune diseases
IL213120A0 (en) Method for treating parkinson' s disease
GB0718918D0 (en) Compositions and methods for treating skin conditions
IL217149A0 (en) Compositions and methods for treating parkinson's disease